Takeda Pharmaceutical Company Limited and HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced a partnership to discover and develop novel therapeutics for liver diseases, including nonalcoholic steatohepatitis (NASH).
The pill form of the drug semaglutide is worth pursuing as a way to control blood sugar in patients with type 2 diabetes, say researchers.
A recent study investigates the ability of an asthma drug to reduce levels of α-synuclein, a protein believed to contribute to the development of Parkinson’s disease.
Neurotech International Ltd has successfully raised $4 million via a placement of shares at $0.20 each to drive its ongoing commercialisation of the Mente Autism device.
A study of the global prevalence of fetal alcohol spectrum disorder (FASD) estimates that it affects as many as 8 out of 10,000 children, highlighting the need to improve public education about the potential harm of drinking alcohol during pregnancy.
US regulators have accepted an application by AstraZeneca and MedImmune to expand the scope of Imfinzi (durvalumab) to include patients with a certain form of lung cancer.
Medical equipment maker MagicMed Technologies (Beijing) Co. has secured USD1.5 million (CNY10 million) in pre-series A financing. The funds will help the firm hasten the commercialization of its Magitor Cell, a single channel electrocardiographic monitoring device.
The review, led by Jerome Pesenti, chief executive of BenevolentTech and Dame Wendy Hall, Professor of Computer Science at the University of Southampton, says AI is expected to make “great improvements” for the public, including more personalised services, better healthcare and more efficient use of resources.
Researchers from Harvard Medical School, Boston Children’s Hospital and Brigham and Women’s Hospital in the US have developed a paediatric surgical implant that grows along with the child.
Spark Therapeutics Inc's experimental gene therapy for a rare form of blindness improves vision and should be approved, advisers to the Food and Drug Administration concluded on Thursday, paving the way for the first U.S. gene therapy for an inherited disease.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.